Bispecific TCRs are engineered proteins that can simultaneously bind two different antigens. Typically, one arm of the bispecific TCR targets a specific tumor antigen, while the other engages a T-cell receptor. This dual-binding capability enables bispecific TCRs to redirect T cells towards cancer cells, enhancing the immune response against the tumor.
